With Sir Andrew Dillon announcing his retirement as chief executive of NICE, pharmaphorum discusses potential replacements for the man who is arguably the most influential figure in health
Bayer’s Xarelto (rivaroxaban) can be funded by the NHS to prevent strokes and heart attacks in high-risk adults with coronary artery disease, NICE has said.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
